+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
PGHL

Procter & Gamble Health Share Price

₹6,144.50 +76.5 (1.26%)
30.54% Gain from 52W Low

07 Aug, 2026 3:54 PM (IST)

Procter & Gamble Health live price: ₹6,144.50. It opened at ₹6,060 vs previous close ₹6,068; intraday high/low: ₹6,170/₹6,009. The 50 & 200 DMA stand at ₹6,325.60/₹5,819.90.

Procter & Gamble Health Performance

  • Today's Low
  • ₹6,009
  • Today's High
  • ₹6,170
  • 52 Week Low
  • ₹4,707
  • 52 Week High
  • ₹6,975
  • Open Price₹6,060
  • Previous Close₹6,068
  • Volume26,057
  • 50 DMA₹6,325.60
  • 100 DMA₹6,030.80
  • 200 DMA₹5,819.90

Procter & Gamble Health Chart

Investment Returns

  • Over 1 Month -1.88%
  • Over 3 Month + 14.74%
  • Over 6 Month + 18.39%
  • Over 1 Year -3.13%

Smart Investing Starts Here Start SIP with Procter & Gamble Health for Steady Growth!

Invest Now

Procter & Gamble Health Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 28.6
  • PEG Ratio
  • 1.5
  • Market Cap Cr
  • 10,200
  • P/B Ratio
  • 19.4
  • Average True Range
  • 200.6
  • EPS
  • 215
  • Dividend Yield
  • 3.3
  • MACD Signal
  • -35.4
  • RSI
  • 35.46
  • MFI
  • 5.76

Latest Stock News Updates

Q1FY27 Quarterly Result Announced for Procter & Gamble Health Ltd.

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Procter & Gamble Health announced Q1FY27 results</strong></span></h3><p><strong>Financial Highlights:</strong></p><ul><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Revenue from Operations:</strong> The company reported revenue from operations of Rs 36,371 lakh in Q1FY27, representing a growth of 7.37% compared to Rs 33,874 lakh in Q1FY26. On a sequential basis, revenue decreased by 1.82% from Rs 37,045 lakh in Q4FY26.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Total Income:</strong> Total income for Q1FY27 stood at Rs 36,759 lakh, an increase of 7.24% over Rs 34,277 lakh in Q1FY26. Compared to Q4FY26, total income saw a marginal decline of 1.83% from Rs 37,445 lakh.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Profit Before Tax (PBT):</strong> The company achieved a PBT of Rs 12,912 lakh in Q1FY27, a significant increase of 45.39% from Rs 8,881 lakh in Q1FY26. Sequentially, PBT declined by 3.07% from Rs 13,321 lakh in Q4FY26. The Q1FY27 PBT includes an exceptional gain of Rs 3,180 lakh.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Net Profit for the Period:</strong> Net profit stood at Rs 9,615 lakh in Q1FY27, registering a growth of 45.29% compared to Rs 6,618 lakh in Q1FY26. On a QoQ basis, net profit grew by 1.64% from Rs 9,460 lakh in Q4FY26.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Total Comprehensive Income:</strong> The total comprehensive income for Q1FY27 was Rs 9,646 lakh, up by 47.20% from Rs 6,553 lakh in Q1FY26 and up 5.23% from Rs 9,167 lakh in Q4FY26.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Earnings Per Share (EPS):</strong> Basic and diluted EPS (after exceptional items) for Q1FY27 was Rs 57.92, compared to Rs 39.87 in Q1FY26 and Rs 56.99 in Q4FY26.</li></ul><p><strong>Business Highlights</strong></p><ul><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Segment Performance:</strong> The company operates in a single primary reportable segment, namely "Pharmaceuticals," as identified under Ind AS 108.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Exceptional Item:</strong> During Q1FY27, the company sold its office premises property in Worli for a total consideration of Rs 3,334 lakh. With the carrying amount of the property at Rs 154 lakh, the transaction resulted in an exceptional gain of Rs 3,180 lakh.</li><li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Audit Opinion:</strong> The statutory auditors, M/s Haribhakti & Co. LLP, have issued a Limited Review Report with an unmodified conclusion on the financial results for the quarter ended June 30, 2026.</li></ul><p><strong>Milind Thatte, Managing Director, P&G Health India, said</strong>, “We are happy to start the Financial Year 2026-2027 on a strong note, carrying forward the growth momentum of the previous fiscal. We delivered a strong quarter with sustained top-line and bottom-line growth. This growth is enabled by the consumer response to our science-backed superior innovations, new consumer communication initiatives and strengthened go-to-market and supply chain capabilities.</p><p>We are delivering balanced growth and value creation for all our stakeholders, driven by our strategy that is centred on a focused portfolio of quality, trusted and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption, productivity, and an agile accountable organization.”</p><p><a class="lb" href="/gujarati/get-document/post/pdf/5768690/" target="_blank">Result PDF</a></p>

Procter & Gamble Health Ltd - 500126 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release on the Unaudited Financial Results for the Quarter ended June 30, 2026.

Procter & Gamble Health Ltd - 500126 - Unaudited Financial Results For The Quarter Ended June 30, 2026

Unaudited Financial Results for the Quarter ended June 30, 2026

Procter & Gamble Health Financials

Procter & Gamble Health Technicals

EMA & SMA

Current Price
₹6,144.50
+ 76.5 (1.26%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹6,497.90
  • 50 Day
  • ₹6,325.60
  • 100 Day
  • ₹6,030.80
  • 200 Day
  • ₹5,819.90

Resistance and Support

6107.83 Pivot Speed
  • R3 6,367.70
  • R2 6,268.80
  • R1 6,206.70
  • S1 6,045.70
  • S2 5,946.80
  • S3 5,884.70

Procter & Gamble Health Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-06 Quarterly Results
2026-05-26 Audited Results & Final Dividend
2026-02-06 Quarterly Results & Interim Dividend
2025-11-05 Quarterly Results & Interim Dividend
2025-08-01 Quarterly Results
Date Purpose Remarks
2026-08-27 FINAL Rs.45.00 per share(450%)Final Dividend (RD & XD dates revised)
2026-02-12 SPECIAL Rs.50.00 per share(500%)Special Dividend
2026-02-12 INTERIM Rs.110.00 per share(1100%)Interim Dividend
2025-08-22 FINAL Rs.45.00 per share(450%)Final Dividend
2025-02-21 INTERIM Rs.80.00 per share(800%)Interim Dividend
View Procter & Gamble Health Dividend History Arrow

Procter & Gamble Health Shareholding Pattern

51.82%
29.41%
9.05%
6.33%
3.39%

Procter & Gamble Health FAQs

Procter & Gamble Health share price is ₹6,144 As on 09 August, 2026 | 22:26

The Market Cap of Procter & Gamble Health is ₹10199.5 Cr As on 09 August, 2026 | 22:26

The P/E ratio of Procter & Gamble Health is 28.6 As on 09 August, 2026 | 22:26

The PB ratio of Procter & Gamble Health is 19.4 As on 09 August, 2026 | 22:26

The 52 week High & Low of Procter & Gamble Health is ₹6975/₹4707 respectively As on 09 August, 2026 | 22:26

Open FREE Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23